- Home
- MAIA vs PEPG Comparison
MAIA vs PEPG Comparison
Compare MAIA & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- PEPG
- Stock Information
- Founded
- MAIA 2018
- PEPG 2018
- Country
- MAIA United States
- PEPG United States
- Employees
- MAIA N/A
- PEPG N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- PEPG Health Care
- Exchange
- MAIA Nasdaq
- PEPG Nasdaq
- Market Cap
- MAIA 56.3M
- PEPG 45.5M
- IPO Year
- MAIA 2022
- PEPG 2022
- Fundamental
- Price
- MAIA $1.70
- PEPG $1.45
- Analyst Decision
- MAIA
- PEPG Buy
- Analyst Count
- MAIA 0
- PEPG 3
- Target Price
- MAIA N/A
- PEPG $7.67
- AVG Volume (30 Days)
- MAIA 468.1K
- PEPG 342.9K
- Earning Date
- MAIA 08-08-2025
- PEPG 08-07-2025
- Dividend Yield
- MAIA N/A
- PEPG N/A
- EPS Growth
- MAIA N/A
- PEPG N/A
- EPS
- MAIA N/A
- PEPG N/A
- Revenue
- MAIA N/A
- PEPG N/A
- Revenue This Year
- MAIA N/A
- PEPG N/A
- Revenue Next Year
- MAIA N/A
- PEPG N/A
- P/E Ratio
- MAIA N/A
- PEPG N/A
- Revenue Growth
- MAIA N/A
- PEPG N/A
- 52 Week Low
- MAIA $1.40
- PEPG $0.88
- 52 Week High
- MAIA $3.74
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- MAIA 44.78
- PEPG 58.91
- Support Level
- MAIA $1.64
- PEPG $1.37
- Resistance Level
- MAIA $1.74
- PEPG $1.47
- Average True Range (ATR)
- MAIA 0.09
- PEPG 0.08
- MACD
- MAIA -0.01
- PEPG 0.03
- Stochastic Oscillator
- MAIA 11.76
- PEPG 94.12
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.